A functional perspective for understanding hub circRNAs as regulators linking metastasis with immune evasion is offered and future efforts to investigate their dual functions in translational settings are guided.
Abstract
Circular RNAs (circRNAs) are a class of highly stable non-coding RNAs that play pivotal roles in cancer progression by concurrently modulating tumor metastasis and immune evasion. Among them, a subset termed hub circRNAs coordinates these two processes within the same tumor context through multiple regulatory mechanisms. Hub circRNAs facilitate tumor cell migration, invasion, and colonization at distant sites, while simultaneously impairing the function of immune effector cells and remodeling the tumor microenvironment into an immunosuppressive state. These dual effects can be propagated to distal microenvironments via extracellular vesicles, thereby amplifying both metastasis and immunosuppression. To organize the available evidence, we propose a provisional three-tiered stringent/convergent/network-informed (S/C/N) evidence-mapping framework that integrates evidence across studies and organizes the type and completeness of functional, mechanistic, and network-informed support. Finally, we highlight current research gaps, outline the potential of hub circRNAs as biomarkers and therapeutic targets, and discuss experimental and methodological considerations for pan-cancer investigations. This review offers a functional perspective for understanding hub circRNAs as regulators linking metastasis with immune evasion and guides future efforts to investigate their dual functions in translational settings.
Improvements in elucidating the molecular mechanisms through which circRNAs influence the efficacy of breast cancer immunotherapy pave the way for improving the prognosis of breast cancer immunotherapy and open new avenues for future research and clinical translation.
Yu Jiang, Ya-Wen Wang, Kai Zhang· Frontiers in Immunology· 0 citations
This review details the role of tumor derived exosomes in shaping an immunosuppressive TME, especially their capacity to modulate T-cell function, polarize myeloid cells, and influence immune checkpoint signalling, and discusses emerging therapeutic strategies aimed at intercepting or reprogramming exosomal cargo.
RamaRao Malla, G. Nagaraju· Biochemical Pharmacology· 0 citations
This review systematically summarize current advances in lncRNA-mediated regulation of cancer metastasis and drug resistance, with particular emphasis on their roles in oncogenic signaling cascades, transcriptional control, immune cell reprogramming, and metabolic remodeling.
Dong Liang, Jing-Wen Zheng, Zheng-Dan Gao et al.· Biochimica et biophysica act...· 0 citations
This work discusses new discoveries which highlight the value of lncRNA targeting as therapeutic applications, in gastrointestinal inflammation and cancer angiogenesis, and identifies gaps in the current knowledge and understanding.
Charlie Leboff, Pamela Calle-Mendoza, M. Hatziapostolou et al.· British Journal of Pharmacol...· 0 citations
Overall, EV-ncRNAs represent promising mechanistic biomarkers and therapeutic targets, but rigorous source-specific validation and standardized analytical workflows are required before clinical implementation.
T. AlRamadneh, Waleed K. Abdulsahib, Sanan Thaer Abdalwahab et al.· Cancer Treatment and Researc...· 0 citations
Current discoveries defining the lncRNA-TIME nexus are synthesized and advances in high-throughput sequencing, single-cell transcriptomics, and computational modeling that enable the mapping of these complex networks are highlighted.
Juwon Lee, R. Nadhan, Yong-Sang Song et al.· Genomics, Proteomics & Bioin...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.